Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;37(10):2138-2141.
doi: 10.1038/s41375-023-02004-w. Epub 2023 Aug 12.

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC

Sandra Huber  1 , Constance Baer  1 , Stephan Hutter  1 , Frank Dicker  1 , Irene Fuhrmann  1 , Manja Meggendorfer  1 , Christian Pohlkamp  1 , Wolfgang Kern  1 , Torsten Haferlach  1 , Claudia Haferlach  1 , Gregor Hoermann  2
Affiliations

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC

Sandra Huber et al. Leukemia. 2023 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CH, WK, and TH declare part ownership of Munich Leukemia Laboratory (MLL). SH, CB, StH, FD, IF, MM, CP and GH are employed by the MLL.

Figures

Fig. 1
Fig. 1. Risk-stratification of MDS/AML patients according to IPSS-M.
A Density plot of IPSS-M risk scores calculated for MDS/AML patients (red; n = 137) and for the bona fide MDS cohort ([8]; green; n = 626). VL: very low, L: low, ML: moderate low, MH: moderate high, H: high, VH: very high. B Overall survival (OS) of the MDS/AML cohort (n = 137) according to IPSS-M risk categories: low/ green (n = 12), moderate low/ brown (n = 9), moderate high/ yellow (n = 14), high/ red (n = 40), very high/ dark red (n = 62); dotted line: median OS; see also C. C Survival data of the IPSS-M risk categories of different cohorts; OS overall survival, NA not available, n number of samples of MDS/AML cohort.
Fig. 2
Fig. 2. Risk-stratification of MDS/AML patients according to ELN 2022 guidelines.
Overall survival (OS) according to ELN 2022 risk categories of the MDS/AML cohort (n = 137; orange line: intermediate risk; purple line: adverse risk) and the AML control group (n = 686; 95% confidence interval included for the different risk categories: favorable/light green, intermediate/light orange, adverse/light purple). NA not available.
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. doi: 10.1182/blood.2022015850. - DOI - PMC - PubMed
    1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19. doi: 10.1038/s41375-022-01613-1. - DOI - PMC - PubMed
    1. Estey E, Hasserjian RP, Döhner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood. 2022;139:323–32. doi: 10.1182/blood.2021011304. - DOI - PMC - PubMed
    1. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood. 2012;120:2454–65. doi: 10.1182/blood-2012-03-420489. - DOI - PMC - PubMed
    1. Bernard E, Tuechler H, Greenberg Peter L, Hasserjian Robert P, Arango Ossa Juan E, Nannya Y, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence. 2022;1:EVIDoa2200008. doi: 10.1056/EVIDoa2200008. - DOI - PubMed

MeSH terms